Moser P

References (4)

Title : Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10-2474 - Bonifacio_2020_Br.J.Pharmacol_177_2123
Author(s) : Bonifacio MJ , Sousa F , Aires C , Loureiro AI , Fernandes-Lopes C , Pires NM , Palma PN , Moser P , Soares-da-Silva P
Ref : British Journal of Pharmacology , 177 :2123 , 2020
Abstract : BACKGROUND AND PURPOSE: In 2016, one person died and four others had mild-to-severe neurological symptoms during a phase I trial of the fatty acid amide hydrolase (FAAH) inhibitor BIA 10-2474. EXPERIMENTAL APPROACH: Pharmacodynamic and pharmacokinetic studies were performed with BIA 10-2474, PF-04457845 and JNJ-42165279 using mice, rats and human FAAH expressed in COS cells. Selectivity was evaluated by activity-based protein profiling (APBB) in rats. BIA 10-2474 effect in stroke-prone spontaneously hypertensive rats (SHRSP) was investigated. KEY RESULTS: BIA 10-2474 was 10-fold less potent than PF-04457845 in inhibiting human FAAH in situ but inhibited mouse brain and liver FAAH with ED(50) values of 13.5 and 6.2 microg.kg(-1) , respectively. Plasma and brain BIA 10-2474 levels were consistent with in situ potency and neither BIA 10-2474 nor its metabolites accumulated following repeat administration. FAAH and alpha/beta-hydrolase domain containing 6 were the primary targets of BIA 10-2474 and, at higher exposure levels, ABHD11, PNPLA6, PLA2G15, PLA2G6 and androgen-induced protein 1. At 100 mg.kg(-1) for 28 days, the level of several lipid species containing arachidonic acid increased. Daily treatment of SHRSP with BIA 10-2474 did not affect mortality rate or increased the incidence of haemorrhage or oedema in surviving animals. CONCLUSIONS AND IMPLICATIONS: BIA 10-2474 potently inhibits FAAH in vivo, similarly to PF-04457845 and interacts with a number of lipid processing enzymes, some previously identified in human cells as off-targets particularly at high levels of exposure. These interactions occurred at doses used in toxicology studies, but the implication of these off-targets in the clinical trial accident remains unclear.
ESTHER : Bonifacio_2020_Br.J.Pharmacol_177_2123
PubMedSearch : Bonifacio_2020_Br.J.Pharmacol_177_2123
PubMedID: 31901141

Title : Poster: Effects of positive allosteric modulators (PAMs) of nicotinic receptors on intracellular Ca2+ concentration [Ca2+]i in mouse embryonic mesencephalic neurons in primary culture -
Author(s) : Cosi C , Marty F , Maillos P , Moser P
Ref : Biochemical Pharmacology , 86 :1226 , 2013
PubMedID:

Title : Expression of neuronal nicotinic acetylcholine receptor mRNA in rat dopaminergic neurons -
Author(s) : Charpantier E , Barneoud P , Moser P , Besnard F , Sgard F
Ref : Journal de Physiologie (Paris) , 92 :418 , 1998
PubMedID:

Title : Poster: Synthesis and biological evaluation of MDL 74,019DG, a centrally active M1 versus M2 selective muscarinic receptor antagonist -
Author(s) : Van Hijfte L , Zerr V , Hibert M , Marciniak G , Moser P , Moran P , Richards MH , van Giersbergen PL
Ref : Life Sciences , 56(11-12) :1013 , 1995
PubMedID: